Managing gout needs more than drugs: 'Il faut le savoir-faire, l'Art et la manière'

Annals of the Rheumatic Diseases

Volumn 72, Issue 6, 2013, Pages 791-793

  Lioté, Frédéric ^a,b   Choi, Hyon ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE VIGGO PETERSEN   (France)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; FEBUXOSTAT; URATE; URIC ACID;

CRYSTALLIZATION; DOCTOR PATIENT RELATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG USE; EDITORIAL; EVIDENCE BASED MEDICINE; GOUT; HEALTH CARE QUALITY; HUMAN; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MEDICATION COMPLIANCE; PATIENT CARE; PATIENT EDUCATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; URIC ACID BLOOD LEVEL;

GOUT; MULTIDISCIPLINARY TEAM-CARE; TREATMENT;

FEMALE; GOUT; HUMANS; MALE; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; RISK REDUCTION BEHAVIOR;

EID: 84877618156     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203226     Document Type: Editorial

References (28)

1. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a taskforce of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11. (Pubitemid 44641591)
2. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a taskforce of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24. (Pubitemid 44620440)
3. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007;46:1372-4.
4. Reach G. Treatment adherence in patients with gout. Joint Bone Spine 2011;78:456-9.
5. Briesacher BA, Andrade SE, Fouayzi H, et al. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008;28:437-43. (Pubitemid 351466455)
6. Singh JA, Alpert MD, Kerr G. A national survey of Veterans Affairs rheumatologists for relevance of quality of care indicators for gout management. Arthritis Care Res (Hoboken) 2010;62:1306-11.
7. Singh JA, Hodges JS, Toscano JP, et al. Quality of care for gout in the US needs improvement. Arthritis Rheum 2007;57:822-9. (Pubitemid 46932089)
8. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2013;72:826-30.
9. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60. (Pubitemid 34856121)
10. Perez-Ruiz F, Lioté F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007;57:1324-8. (Pubitemid 47585481)
11. Baraf HS, Matsumoto AK, Maroli AN, et al. Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum 2008;58:3632-4.
12. Jansen TL, Richette P, Perez-Ruiz F, et al. International position paper on febuxostat. Clin Rheumatol 2010;29:835-40.
13. Vázquez-Mellado J, Morales EM Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-3. (Pubitemid 32885676)
14. Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-50. (Pubitemid 44168841)
15. Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011;63:412-21.
16. Reinders MK, van Roon EN, Houtman PM, et al. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol 2007;26:1459-65. (Pubitemid 47201684)
17. Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009;68:51-6.
18. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012;64:2529-36.
19. Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007;66:1311-15. (Pubitemid 47492473)
20. Mohan AV, Phillips LS. Clinical inertia and uncertainty in medicine. JAMA 2011;306:383; author reply 383-4.
21. Simon D. Therapeutic inertia in type 2 diabetes: insights from the PANORAMA study in France. Diabetes Metab 2012;38(Suppl 3):S47-52.
22. Avignon A, Attali C, Sultan A, et al. Clinical inertia: viewpoints of general practitioners and diabetologists. Diabetes Metab 2012;38(Suppl 3):S53-8.
23. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis 2012;71:1490-5.
24. Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis 2012;71:1765-70.
25. Harrold LR, Mazor KM, Velten S, et al. Patients and providers view gout differently: a qualitative study. Chronic Illn 2010;6:263-71.
26. Benhamou PY. Improving diabetes management with electronic health records and patients' health records. Diabetes Metab 2011;37(Suppl 4):S53-6.
27. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res(Hoboken) 2012;64:1447-61.
28. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431-46.